Illuminaの空売り状況は、投資家がIlluminaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Illumina (NASDAQ:ILMN) 株価情報, 空売り情報

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

News

Movers

COHR

COIN

CRWD

ESTC

GWRE

ILMN

NVDA

PLTR

RDDT

SAIA

大手株式のうち、先週利益が最も伸びた企業に投資していますか。以下は、先週における最大手株式の上位パフォーマンスについてのリストです。

アームとボーイング　大手株の中で大幅な上昇を記録

Illumina Inc

Illumina Inc COM-WHEN ISSUED

Longstanding partners bring together end-to-end workflows and leading CRISPR Perturb-seq technologies setting a standard for single-cell studies and enabling a 5 billion single-cell atlas ecosystem within three years
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows.&nbsp;

Biotech

General

Illumina Collaborates With Broad Clinical Labs To Rapidly Streamline And Scale Single-Cell Projects With Cutting-Edge Tools And Workflows

Hedge Funds

Carl Icahn Cuts Shared Share Stake In Illumina Inc. By 90.7% To 40,000 Shares

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $150 to $136.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $136

Ark Invest, led by Cathie Wood, made significant trades on Monday. Among the most prominent was the sale of shares in Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), as the stock continued its upward trajectory following impressive financial results.
The Palantir Trade
On Monday, Ark Invest executed a notable trade involving Palantir selling 135,775 shares through its ARKK ETF. This move comes after <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock">Palantir&#8217;s stock reached new all-time highs</a> following its impressive <a href="https://in.benzinga.com/news/earnings/earnings-beats/25/02/43468342/palantir-rockets-on-strong-q4-2024-was-only-a-dress-rehearsal-for-ai-growth-says-analyst">fourth-quarter earnings report</a>. The company reported revenue of $827.52 million, surpassing analyst expectations of $775.91 million, and adjusted earnings of 14 cents per share, beating the forecast of 11 cents per share.
The stock closed at $116.65 on Monday, marking a 5.23% increase. The 52-week high for the stock is $116.76. In the after-hours trading, it was seen at $117.56. The sale of these shares amounted to approximately $15.83 million, based on Monday&#8217;s closing price. Despite the impressive financial results, Ark Invest has been <a href="https://www.benzinga.com/25/02/43550434/cathie-wood-dumps-10-million-palantir-shares-at-peak-sells-robinhood-and-reddit-ark-invest-loads-up-on-qualcomm-stock">strategically reducing</a> its position in Palantir.
Other Key Trades:
<ul>
<li>UiPath Inc. (PATH) &#8211; Sold 459,205 shares through ARKK and 33,061 shares through ARKW.</li>
<li>Roku Inc.(ROKU) &#8211; Sold 78,654 shares through ARKK.</li>
<li>Twist Bioscience Corp. (TWST) &#8211; Bought 268,210 shares through ARKK.</li>
<li>Illumina Inc. (ILMN) &#8211; Bought 85,621 shares through ARKK and 14,846 shares through ARKG.</li>
</ul>
Image via Shutterstock
Read Next: 
<ul>
<li><a href="https://in.benzinga.com/markets/equities/25/02/43613133/trumps-25-tarrifs-a-self-inflicted-wound-says-economist-amid-warnings-of-fewer-american-jobs-peter-schiff-says-youll-pay-more-for-cars-and-homes">Trump&#8217;s 25% Tarrifs A &#8216;Self-Inflicted Wound,&#8217; Says Economist Amid Warnings Of Fewer American Jobs — Peter Schiff Says You&#8217;ll Pay More For Cars And Homes</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Markets

ETFs

PATH

ROKU

TWST

Cathie Wood Dumps $16 Million Worth Of Palantir Stock After Record Highs

Deep-pocketed investors have adopted a bullish approach towards Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ILMN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Illumina. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to $288,673.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $155.0 for Illumina over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Illumina stands at 41.75, with a total volume reaching 2,466.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Illumina, situated within the strike price corridor from $90.0 to $155.0, throughout the last 30 days.
<h3>Illumina Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739210439_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.9</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$90.00</td>
<td>$212.2K</td>
<td align="right">35</td>
<td align="right">232</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$6.2</td>
<td>$4.8</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$109.4K</td>
<td align="right">0</td>
<td align="right">202</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.3</td>
<td>$21.1</td>
<td>$22.3</td>
<td>$100.00</td>
<td>$66.9K</td>
<td align="right">122</td>
<td align="right">80</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$1.45</td>
<td>$1.1</td>
<td>$1.3</td>
<td>$105.00</td>
<td>$65.0K</td>
<td align="right">0</td>
<td align="right">591</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$6.6</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$104.00</td>
<td>$60.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Illumina</h3>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Illumina Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,059,976, the price of ILMN is down by -6.0%, reaching $104.4.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 80 days from now.</li>
</ul>
<h3>What The Experts Say On Illumina</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $170.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Illumina with a target price of $150. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Hold rating on Illumina with a target price of $135. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Illumina, maintaining a target price of $247. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Illumina, maintaining a target price of $190. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Illumina with a target price of $130. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Illumina, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Illumina's Options Activity: What's the Big Picture?

WIIM

Illumina shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and cut its price target on the stock from $130 to $100.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst John Freeman downgraded ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Strong Buy to Outperform and lowered the price target from $157 to $124. ConocoPhillips shares closed at $98.36 on Friday. <a href="https://www.benzinga.com/quote/COP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Luke Sergott downgraded Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Equal-Weight to Underweight and lowered the price target from $130 to $100. Illumina shares closed at $111.06 on Friday. <a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst David Lebowitz downgraded Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Neutral and lowered the price target from $44 to $4. Pliant Therapeutics shares closed at $7.79 on Friday. <a href="https://www.benzinga.com/quote/PLRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Jon Windham downgraded the rating for Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Buy to Neutral and maintained the price target of $5. Altus Power shares closed at $4.87 on Friday. <a href="https://www.benzinga.com/quote/AMPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Mehdi Hosseini downgraded NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Positive to Neutral and lowered the price target from $155 to $130. NetApp shares closed at $122.91 on Friday. <a href="https://www.benzinga.com/quote/NTAP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ILMN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-1024x602.png" alt="" class="wp-image-774960" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Downgrades

Trading Ideas

AMPS

NTAP

PLRX

This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and raises the price target from $185 to $190.

Piper Sandler Maintains Overweight on Illumina, Raises Price Target to $190

Throughout the last three months, 7 analysts have evaluated Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Illumina and provided 12-month price targets. The average target is $153.86, accompanied by a high estimate of $247.00 and a low estimate of $100.00. This current average has decreased by 9.19% from the previous average price target of $169.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1739196041_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Illumina's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$247.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Illumina. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Illumina's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Illumina's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Financial Insights: Illumina</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Illumina faced challenges, resulting in a decline of approximately -3.49% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 65.28%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Illumina's ROE stands out, surpassing industry averages. With an impressive ROE of 39.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Illumina's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 11.66%, the company showcases efficient use of assets and strong financial health.
Debt Management: Illumina's debt-to-equity ratio surpasses industry norms, standing at 1.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Illumina In The Eyes Of 7 Experts

Barclays analyst Luke Sergott downgrades Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Equal-Weight to Underweight and lowers the price target from $130 to $100.

Barclays Downgrades Illumina to Underweight, Lowers Price Target to $100

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) stock declined 25.99% after the company reported first-quarter earnings and issued second-quarter guidance below estimates. Analysts revised <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) stock plummeted 22.05%  after the company <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares tumbled 19.23% after the company missed its fourth-quarter revenue <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">estimate when reporting financial results</a>. Additionally, HC Wainwright &amp; Co. and B of A Securities lowered <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">their respective price forecasts on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares fell 17.30%, probably after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.&#8217;s nomination to the Senate floor.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) stock was down 16.33% after the company <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">reported fourth-quarter results</a>. Analysts lowered <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) stock decreased 14.23%, probably after President Trump reiterated a pledge to increase oil production.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) shares declined 14.01% after the company reported fourth-quarter results and <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">missed its adjusted EPS estimate</a>.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) stock tumbled 12.72% after the company reported fourth-quarter results and analysts <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>IDEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) shares fell 12.65% following mixed <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts revised <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) shares declined 12.64% after the company reported first-quarter financial results, issued guidance below <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">estimates and cut its FY25 guidance</a>.</li>
</ol>
Photo by Lets Design Studio via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

AVTR

MRNA

NBIX

PYPL

SWKS

Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $250 to $247.

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $247

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported better-than-expected results for its fourth <a href="https://www.benzinga.com/quote/ILMN/earnings">quarter on Thursday</a>.
The company posted quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 92 cents per share. The company reported quarterly sales of $1.10 billion which beat the analyst consensus estimate of $1.08 billion.
&#8220;The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, margin expansion, and EPS growth,&#8221; said Jacob Thaysen, Chief Executive Officer. &#8220;For 2025, we will continue our transformation, executing our refreshed strategy that prioritizes a sharp focus on customers and our own operational excellence in order to drive Illumina forward.&#8221;
Illumina said it sees FY2025 adjusted earnings of $4.50 to $4.65 per share, versus estimates of $4.13 per share. The company affirmed FY2025 sales guidance of $4.28 billion to $4.40 billion.
Illumina shares fell 8.2% to trade at $112.77 on Friday.
These analysts made changes to their price targets on Illumina following earnings announcement.
<ul>
<li>Guggenheim analyst Subbu Nambi maintained Illumina with a Buy and lowered the price target from $170 to $150.</li>
<li>Canaccord Genuity analyst Kyle Mikson maintained the stock with a Hold and lowered the price target from $145 to $135.</li>
</ul>
Considering buying ILMN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07142134/image-69-1024x575.png" alt="" class="wp-image-772565" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07142134/image-69-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07142134/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07142134/image-69-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/07142134/image-69.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43558786/how-to-earn-500-a-month-from-mcdonalds-stock-ahead-of-q4-earnings">How To Earn $500 A Month From McDonald&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Illumina Analysts Slash Their Forecasts Following Q4 Results

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity cut Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) price target from $145 to $135. Canaccord Genuity analyst Kyle Mikson maintained a Hold rating. Illumina shares closed at $122.80 on Thursday. <a href="https://www.benzinga.com/quote/ILLMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. raised the price target for The Ensign Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) from $155 to $160. Stephens &amp; Co. analyst Raj Kumar maintained an Overweight rating. Ensign shares closed at $135.91 on Thursday. <a href="https://www.benzinga.com/quote/ENSG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald boosted Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) price target from $111 to $149. Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral rating. Cloudflare shares closed at $141.52 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark cut the price target for Weatherford International plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) from $140 to $125. Benchmark analyst Kurt Hallead maintained a Buy rating. Weatherford International shares closed at $65.36 on Thursday. <a href="https://www.benzinga.com/quote/WFRD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised the price target for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from $140 to $155. Goldman Sachs analyst Christine Cho maintained a Neutral rating. Yum! Brands shares closed at $144.01 on Thursday. <a href="https://www.benzinga.com/quote/YUM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank slashed Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) price target from $150 to $140. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Qualys shares settled at $140.71 on Thursday. <a href="https://www.benzinga.com/quote/QLYS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer raised Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) price target from $210 to $235. Oppenheimer analyst Jed Kelly maintained an Outperform rating. Expedia shares closed at $172.57 on Thursday. <a href="https://www.benzinga.com/quote/EXPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) price target from $190 to $220. Raymond James analyst Andrew Marok reiterated an Outperform rating. Take-Two shares closed at $183.08 on Thursday.  <a href="https://www.benzinga.com/quote/TTWO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Tigress Financial raised the price target for Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) from $270 to $330. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Royal Caribbean Cruises shares settled at $270.20 on Thursday. <a href="https://www.benzinga.com/quote/RCL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $236 to $287. Rosenblatt analyst Barton Crockett maintained a Buy rating. Amazon shares closed at $238.83 on Thursday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43558786/how-to-earn-500-a-month-from-mcdonalds-stock-ahead-of-q4-earnings">How To Earn $500 A Month From McDonald&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

AMZN

ENSG

EXPE

QLYS

TTWO

WFRD

Amazon To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Friday

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and lowers the price target from $145 to $135.

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $135

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade <a href="https://www.benzinga.com/topic/tariffs">tariffs eroded risk appetite. </a>
The first warning sign came from the University of Michigan's consumer sentiment survey, which revealed an "unusually large" spike in inflation expectations. The one-year inflation outlook surged by a full percentage point to 4.3%, marking its highest <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">level since November 2023. </a>
Investor uncertainty grew following President Donald Trump's announcement that &#8216;reciprocal tariffs&#8217; would take effect next week. Trump is expected to sign new executive orders at 2:00 p.m. Friday.
On the macro front, February&#8217;s jobs report revealed a mixed outcome, with employment growth slowing down more than expected, yet unemployment fell more than expected, and wages surged more than expected.
Market reaction was swift. The S&amp;P 500 fell 0.6%, erasing its weekly gains, while the Nasdaq 100 dropped 0.9% by 1:00 p.m. trading in New York. 
The Dow Jones Industrial Average slipped into negative territory for the week, putting its three-week winning streak at risk. Small-cap stocks underperformed, with the Russell 2000 sinking 1.3%. 
Stock-wise, Uber Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>) skyrocketed by 9.5%, extending its 8.6% rally from the previous session, after hedge fund billionaire Bill Ackman revealed a stake of 30.3 million shares in the ride-hailing giant.
In currency and bond markets, the U.S. dollar index – tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – rallied following the tariff headlines, while Treasury yields climbed higher. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) dropped 0.8%, reflecting renewed pressure on long-duration bonds. 
Gold took a breather, retreating under pressure from a stronger dollar. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) erased early session gains, slipping from an intraday high of $100,000 to $97,500.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,047.11</td>
<td>-0.6%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,452.38</td>
<td>-0.7%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,576.82</td>
<td>-0.9%</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,279.74</td>
<td>-1.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;fell 0.6% to $602.79.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $444.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;dropped 0.8% up to $528.47.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $229.55.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.7%; the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included:
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): down 3.78%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>): down 8.29%</li>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>): up 2.86%</li>
<li>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>): up 15.22%</li>
<li>Take-Two Interactive Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>): up 14.92%</li>
<li>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): up 7.06%</li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>): up 17.09%</li>
<li>SS&amp;C Technologies Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>): up 5.44%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): up 1.55%</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>): up 2.12%</li>
<li>AptarGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>): down 7.08%</li>
<li>Post Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>): up 5.96%</li>
<li>Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>): down 1.53%</li>
<li>Boyd Gaming Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>): down 0.76%</li>
<li>Encompass Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>): up 1.53%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): down 0.32%</li>
<li>Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>): up 18.39%</li>
<li>Skechers USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>): down 12.68%</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>): up 23.22%</li>
<li>e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): down 21.12%</li>
<li>Fortive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>): down 1.64%</li>
<li>Kimco Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>): up 0.20%</li>
<li>Avantor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>): down 9.52%</li>
<li>Plains All American Pipeline LP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>): down 2.65%</li>
<li>Cboe Global Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NASDAQ">CBOE</a>): up 1.03%</li>
<li>Construction Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>): up 6.75%</li>
<li>Plains GP Holdings LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NYSE">PAGP</a>): down 1.56%</li>
<li>Flowers Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>): up 0.31%</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>): down 28.38%</li>
<li>Perella Weinberg Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>): down 6.50%</li>
<li>Frontier Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>): up 16.75%</li>
<li>Proto Labs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>): down 1.89%</li>
<li>Green Plains Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>): down 19.06%</li>
<li>Graham Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>): down 17.34%</li>
<li>GrafTech International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>): down 4.70%</li>
<li>Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): down 25.18%</li>
<li>Iterum Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>): down 5.03%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43567475/amazon-vs-walmart-did-amazons-q4-revenue-beat-the-worlds-largest-retailer">Amazon Vs. Walmart: Did Amazon&#8217;s Q4 Revenue Beat &#8216;The World&#8217;s Largest Retailer&#8217;?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Commodities

Forex

Econ #s

Economics

Tech

$BTC

AFRM

CBOE

SPDR Dow Jones Industrial Average ETF Trust

FTNT

GPRE

ITRM

MPWR

PAGP

PINS

POST

PRLB

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

ROAD

SSNC

iShares Trust Barclays 20+ Year Treasury Bond Fund

UBER

ULCC

PowerShares DB US Dollar Index Bullish Fund

VRSN

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and lowers the price target from $170 to $150.

Guggenheim Maintains Buy on Illumina, Lowers Price Target to $150

U.S. stock futures were mixed this morning, with the Dow Jones futures gaining around 0.1% on Friday.
Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter financial results and issued first-quarter guidance <a href="https://www.benzinga.com/quote/SKX/earnings">below estimates</a>.
Skechers reported quarterly earnings of 65 cents per share which missed the analyst consensus estimate of 74 cents per share. The company reported quarterly sales of $2.21 billion which missed the analyst consensus estimate of $2.22 billion.
Skechers U.S.A. shares dipped 12.1% to $66.49 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) shares fell 28.4% to $68.89 in pre-market trading after the company issued third-quarter total revenue guidance below estimates.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares tumbled 25.2% to $66.17 in pre-market trading after the company issued FY25 guidance below estimates.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) fell 22% to $0.0660 in pre-market trading.</li>
<li>LiveRamp Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) declined 15.4% to $30.01 in pre-market trading as the company posted third-quarter results.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) shares dipped 11.7% to $20.51 in pre-market trading. Concentra&#xAE; Group Holdings Parent will release the financial results for its fourth quarter on Monday, March 3, after the closing bell.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 8.1% to $13.52 in pre-market trading. CVRx recently reported mixed fourth-quarter financial results.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) fell 6.6% to $49.60 in pre-market trading as the company reported weaker-than-expected third-quarter financial results and issued weak earnings guidance for the fourth quarter.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) declined 4.6% to $117.20 in pre-market trading following fourth-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in">Jim Cramer Says Don&#8217;t Buy This Financial Stock At This Level: &#8216;Let It Come In&#8217;</a></li>
</ul>

Pre-Market Outlook

BILL

CVRX

MCHP

RAMP

Skechers Posts Downbeat Results, Joins e.l.f. Beauty, LiveRamp And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Illumina shares are trading lower. The company reported Q4 financial results.

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported its Q4 earnings results on Thursday, February 6, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Illumina beat estimated earnings by 3.0%, reporting an EPS of $0.95 versus an estimate of $0.92.
Revenue was down $18.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.26 in the previous quarter, leading to a 1.0% increase share price change the next day.
Here's a look at Illumina's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.88</td>
<td>0.90</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.14</td>
<td>0.36</td>
<td>0.09</td>
<td>0.14</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.08B</td>
<td>1.08B</td>
<td>1.05B</td>
<td>1.09B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.08B</td>
<td>1.11B</td>
<td>1.08B</td>
<td>1.12B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Illumina management provided guidance for FY 2025, expecting earnings between $4.5 and $4.65 per share.
To track all earnings releases for Illumina <a href="https://www.benzinga.com/quote/ILMN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Illumina Earnings Report: Q4 Overview

Press Releases

Ovation.io and Illumina Collaborate to Advance Genomic Data Research

Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications

Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025

Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Illumina and NVIDIA collaborate to decode biology and propel precision health

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024

Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference

Illumina unveils first-of-its-kind spatial transcriptomics technology

Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

空売り

Illumina (NASDAQ:ILMN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル